MOTS-c Peptide Shows Promise for Age-Related Macular Degeneration Treatment
Background
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss, particularly in older adults, characterized by damage to the macula, the central part of the retina responsible for sharp, detailed vision. Mitochondrial dysfunction is increasingly recognized as a critical factor in AMD pathogenesis, contributing to retinal pigment epithelial (RPE) cell death, inflammation, and the accumulation of cellular debris. However, the therapeutic potential of mitochondrial-derived peptides like MOTS-c in directly addressing these cellular deficits and restoring mitochondrial health in AMD models remains underexplored.
Results
The study found that MOTS-c treatment significantly improved cellular health and mitochondrial function in the in vitro models of AMD. It demonstrated protective effects against oxidative stress, a key contributor to retinal damage, by enhancing cellular resilience and reducing reactive oxygen species. MOTS-c treatment consistently enhanced cell viability and reduced markers of cellular damage in both RPE cells and patient-derived cybrids, suggesting a direct beneficial impact on mitochondrial health and cellular survival. Specifically, MOTS-c appeared to mitigate mitochondrial dysfunction, which is often observed in AMD pathology, by supporting energy production pathways and maintaining mitochondrial integrity. These findings indicate that the peptide can potentially restore cellular homeostasis and protect against the progressive degeneration seen in compromised retinal cells.
Why It Matters
This research highlights MOTS-c as a promising novel therapeutic candidate for age-related macular degeneration (AMD), addressing the critical need for treatments that target the underlying mitochondrial dysfunction. By improving cellular viability, mitigating oxidative stress, and restoring mitochondrial function, MOTS-c offers a unique approach to preserving retinal health and potentially slowing disease progression. These preclinical findings suggest that MOTS-c could potentially be developed into a new treatment to slow or prevent vision loss in AMD patients, offering hope beyond current limited therapies. Future research should focus on in vivo animal models to confirm efficacy and safety, paving the way for potential human clinical trials.